Evidence map›Paper›PMID 31524498›Full record

Trial reportCirculation2019

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin and 17 more

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02653482. Cited by 204 papers, 41 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 41 pooled it
41.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02653482 phase4completed

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Ran2016Enrolled263Registered outcomes11Posted comparisons0ConditionsChronic Heart Failure With Reduced Systolic FunctionArmsdapagliflozin, dapagliflozin matching Placebo
Open the trial in the graph
NCT05618223 phase3unknown statusstarted 2022, after this paper: background citation

Dapagliflozin Effect on Rheumatic Mitral Stenosis

Ran2022Enrolled36Registered outcomes4Posted comparisons0ConditionsHeart Failure, Mitral Stenosis, Rheumatic Heart DiseaseArmsdapagliflozin
PMID 33749310PMID 28447181PMID 24603967PMID 22305814PMID 34007324other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 41 syntheses or guidelines pooled it, 422 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 6 countries.

Michael E NassifSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Sheryl L WindsorSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Fengming TangSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Yevgeniy KharitonSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Mansoor HusainToronto General Hospital Research Institute, University Health Network, Toronto, Canada (M.H.).
Silvio E InzucchiYale University School of Medicine, New Haven, CT (S.E.I.).
Darren K McGuireUniversity of Texas Southwestern Medical Center, Dallas (D.K.M., M.H.D.).
Bertram PittUniversity of Michigan School of Medicine, Ann Arbor (B.P.).
Benjamin M SciricaCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.M.S., M.M.G.).
Bethany AustinSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Mark H DraznerUniversity of Texas Southwestern Medical Center, Dallas (D.K.M., M.H.D.).
Michael W FongKeck School of Medicine of USC, University of Southern California, Los Angeles (M.W.F.).
Michael M GivertzCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.M.S., M.M.G.).
Robert A GordonNorthShore University, Evanston, IL (R.A.G.).
Rita JermynSt. Francis Hospital, Roslyn, NY (R.J.).
Stuart D KatzNew York University Langone Health, New York (S.D.K.).
Sumant LambaFirst Coast Cardiovascular Institute, Jacksonville, FL (S.L.).
David E LanfearHenry Ford Hospital, Detroit, MI (D.E.L.).
Shane J LaRueWashington University School of Medicine, St. Louis, MO (S.J.L.).
JoAnn LindenfeldVanderbilt University, Nashville, TN (J.L.).
Michael MaloneCharlotte Heart Group Research Center, Port Charlotte, FL (M.M.).
Kenneth MarguliesUniversity of Pennsylvania, Philadelphia (K.M.).
Robert J MentzDuke University, Durham, NC (R.J.M.).
R Kannan MutharasanNorthwestern University, Chicago, IL (R.K.M.).
Michael PursleyHeart Group of the Eastern Shore, Fairhope, AL (M.P.).
Guillermo UmpierrezEmory University, Atlanta, GA (G.U.).
Mikhail KosiborodSaint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., S.L.W., F.T., Y.K., B.A., M.K.).
Saint Luke's Hospital · USBrigham and Women's Hospital · USSouthwestern Medical Center · USDuke University · USEmory University · USFirst Coast Cardiovascular Institute · USForthnet (Greece) · GRHenry Ford Hospital · USImaging the World · USNorthShore University HealthSystem · USNorthwestern University · USNYU Langone Health · USSacred Heart University · USSaint Luke's Health System · USSt. Francis Hospital · USUniversity Health Network · CAUniversity of Michigan · USUniversity of Southern California · USUNSW Sydney · AUVanderbilt University · US

Funding

Technologies Advancing Translation - Regional CoreP30DK111024 · EMORY UNIVERSITY · 2025 to 2025
$775k
NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

backgroundOutcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown.

methodsDEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m

resultsPatient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036-1238) vs 1191 pg/dL (95% CI 1089-1304),

conclusionsIn patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides. Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients without type 2 diabetes mellitus. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT02653482.

Indexed as

AgedBenzhydryl CompoundsBiomarkersDiabetes Mellitus, Type 2FemaleGlucosidesHeart FailureHumansMaleMiddle AgedStroke VolumeVentricular Dysfunction, LeftVentricular Function, LeftBenzhydryl CompoundsBiomarkersdapagliflozinGlucosidesbiomarkershealth statusheart failureoutcomesSGLT2 inhibitors

Identifiers

PMID31524498
OpenAlexW2989060738

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.